UCB announces retirement of Executive Vice President and General Counsel and appointment of successor | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB announces retirement of Executive Vice President and General Counsel and appointment of successor

  • Anna Richo to assume responsibilities of Bob Trainor as he retires after stellar service

Brussels – October 12 – UCB announced today that Anna S. Richo will join the company as Executive Vice President and General Counsel on November 1. Anna will be a member of UCB’s Executive Committee; she will report to Roch Doliveux, UCB’s CEO and Chairman of the Executive Committee. Anna succeeds Bob Trainor, UCB’s EVP and General Counsel since 2004, who will retire at the end of the year.

Anna Richo joins UCB from Amgen Inc. where since 2008 she was Senior Vice President and Chief Compliance Officer reporting to the President and CEO and to Amgen’s Corporate Responsibility & Compliance Committee of the Board of Directors. For the preceding 5 years she was Vice President Law at Amgen Inc. responsible for managing the company’s corporate litigation and law department operations. Prior to joining Amgen, Anna spent 12 years at Baxter Healthcare Corporation where she held various Law positions and ultimately was Vice President, Law for the BioScience business. Her role there included worldwide responsibility for all legal services at Baxter BioScience, including commercial transactions, mergers and acquisitions, intellectual property, international trade and customs and government affairs.

Anna Richo received her Juris Doctor degree from DePaul University, College of Law (Illinois) and her Bachelor’s degree in Industrial and Labor Relations from Cornell University (New York).

“I am very happy to welcome Anna’s wealth of legal and leadership qualities, which will be a great natural fit with the global teams Bob has led, as well as with UCB’s ongoing journey to becoming the patient-centric global biopharma leader,” said Roch Doliveux. “At the same time it is with immense appreciation and regret that we say goodbye to Bob, who has been instrumental in driving UCB’s transformation,” he added.

During his eight-year tenure at UCB, Executive Committee member Bob Trainor has built a strong Legal, IP and Compliance team. His contribution to numerous areas including acquisitions, divestments, intellectual property and compliance has been of great value to UCB. Bob’s extensive experience and sound advice meant he was a mentor and sounding board to many UCB people across the globe.

For further information

France Nivelle, Global Communications, UCB
T +32 2 559 9178, france.nivelle@ucb.com

Laurent Schots, Media Relations, UCB
T +32.2.559.9264,

Notes to the editor

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-Looking Statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Asset Download

Stay up-to-date on the latest news and information from UCB